Patients without chronic kidney disease (CKD) (Table 1, group eGFR ≥60/Alb−) most commonly used renin-angiotensin-aldosterone-system inhibition (RAASi) (59%), followed by β-blockers (39%), and thiazide diuretics (32%). Here, REN is linked to chronic kidney disease.